The collaboration focuses on strengthening diagnostic and treatment capabilities, aligning clinical practices, and enhancing professional training in lung, prostate, and hematologic cancers.The partnership will include hospital-based programs such as scientific forums, targeted training, and practice-alignment initiatives aimed at improving early detection, supporting evidence-based decision-making, and promoting more consistent care pathways.Cancer remains a major public health challenge in Vietnam. Accord ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

The Dow Jones Industrial Average (^DJI) was down 793.47 (-1.73%) points today, closing at 45,166.64. This sharp decline was echoed in Dow Futures (YM=F), which dropped 809.00 (-1.75%) to 45,421.00. The dominant narrative driving the market was the release of the Personal Consumption Expenditures (PCE) price index, which showed inflation accelerating faster than anticipated. This data suggests the Federal Reserve may maintain restrictive interest rates throughout 2026, triggering a broad-based liquidation of ...

Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an oncology injectable has achieved this milestone on the continent. Through this Type II label change, approved by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), Darzalex will now become available to European patients for either patient or caregiver administration after the fifth dose, provided the u ...

Key Takeaways J&J's Innovative Medicine unit is expected to post Q1 growth despite Stelara LOE impactJNJ's growth likely driven by Darzalex, Tremfya, Erleada and the uptake of newer therapies like CarvyktiJNJ faces pressure from Stelara biosimilars, Imbruvica decline and Part D redesign headwindsJohnson & Johnson (JNJ) , via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, ...

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling for DARZALEX® ...

Johnson & Johnson (NYSE:JNJ) is included among the Dividend Kings and Aristocrats List: 32 Biggest Stocks. Johnson & Johnson (JNJ) Gains Spot on Wolfe Favorites amid Growth Outlook Johnson & Johnson (NYSE:JNJ) was included in Wolfe Research’s favorite stocks list, according to a CNBC report published on March 16. The company currently offers a dividend yield of around 2.15%, and last increased its payout in May 2025. The report mentioned that earlier this year, Johnson & Johnson reached an agreement wit ...

An updated edition of the February 5, 2026, article.The global oncology market is entering a period of rapid evolution, fueled by rising cancer incidence, aging populations and continued scientific breakthroughs. According to the American Cancer Society, the United States alone is projected to record approximately 2.1 million new cancer cases and more than 626,000 deaths in 2026. On a global scale, increasing exposure to lifestyle-related risk factors—such as smoking, obesity, and sedentary behavior— and de ...

New Brunswick, New Jersey-based Johnson & Johnson (JNJ) engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. The company has a market cap of $577.9 billion and is expected to release its Q1 2026 earnings on April 14, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $2.69 on a diluted basis, down 2.9% from $2.77 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its ...

Key Takeaways J&J advanced its pipeline in 2025 with key approvals across oncology and immunologyJNJ secured approvals for Inlexzoh, Imaavy and Icotyde, expanding treatment options and pipeline depthJNJ's new cancer drugs generated $3B in 2025, with more growth expected from launches in 2026Johnson & Johnson (JNJ) has a strong R&D pipeline, with primary focus areas being immunology, oncology and neuroscience. J&J rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones ...